CardioExchange Archive

April 28th, 2015

Cardiovascular Outcomes with Sitagliptin: No Better or Worse Than Conventional Care

Larry Husten, PHD

Late Monday afternoon, Merck released the top line results of TECOS, the cardiovascular outcomes trial with its diabetes drug sitagliptin (Januvia).  The company said that the trial “achieved its primary endpoint of non-inferiority for the composite cardiovascular (CV) endpoint.” Merck announced only one additional detail: “Among secondary endpoints,” they reported, “there was no increase in hospitalization for heart […]

---

July 3rd, 2014

Sitagliptin Associated with Increase in Heart Failure Hospitalizations

Larry Husten, PHD

The cardiovascular effects of drugs used for glucose control in patients with diabetes have been a subject of controversy for many years now. More recently, attention has started to focus specifically on the risk for heart failure (HF). Now, an observational study will likely raise new questions about the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin (Januvia, Merck). In […]

---

May 20th, 2013

Selections from Richard Lehman’s Literature Review: May 20th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the safety and efficacy of sitagliptin for type 2 diabetes, use of glucocorticoids and the risk of VTE, and forced smoking abstinence.

---

October 7th, 2011

FDA Approves Juvisync, Combination of Sitagliptin and Simvastatin

Larry Husten, PHD

The FDA has approved a fixed-dose combination tablet consisting of sitagliptin and simvastatin, two drugs previously approved for type 2 diabetes and hypercholesterolemia. Merck will market the new drug as Juvisync. “This is the first product to combine a type 2 diabetes drug with a cholesterol lowering drug in one tablet,” said Mary H. Parks, the […]

---